In line with this assumption, a recent report showed that zinc metallochaperones (ZMCs), a new class of anti-cancer drugs that specifically reactivate zinc-deficient mutant p53 by restoring zinc binding, significantly improve the survival of mice bearing tumors harboring a zinc-deficient missense mutant TP53 allele [334]. This evidence concerns the gene TP53 and cancer.